3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
46
Lymphoma, Mantle-Cell
20
Lymphoma, Follicular
13
Waldenstrom Macroglobulinemia
12
Lymphoma, Non-Hodgkin
12
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma
11
Lymphoma, B-Cell
10
Leukemia
9
Recurrence
8
Multiple Myeloma
5
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphoid
4
Leukemia, B-Cell
4
Hodgkin Disease
4
Bronchiolitis Obliterans Syndrome
4
Hematologic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Prolymphocytic
2
Leukemia, Myeloid, Acute
2
Graft vs Host Disease
2
Chromosome 17 deletion
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Interventions
Rituximab
4
Cyclophosphamide
4
ponatinib
2
Vorinostat
2
Vincristine
2
Prednisone
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bortezomib
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine
1
durvalumab
1
cobomarsen
1
acalabrutinib
1
Melphalan
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Ifosfamide
1
Hsp90 inhibitor KU757
1
Cytarabine
1
Carmustine
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Immune System Diseases
×
ibrutinib
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts